semaglutide canada patent expiry Canada: Generic Access on the Horizon Massive Rs 50,000 Cr Opportunity

Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), history of pancreatitis, pregnancy or breastfeeding, and severe gastrointestinal disorders such as gastroparesis

However, those monthly fees pay for something that copays cannot, and thats recurrent access to a medical professional throughout treatment

These controls are especially useful for those who move between phone, tablet, and desktop, and for anyone who travels frequently and signs in from new networks

In contrast, bowel obstruction symptoms are usually severe, persistent, and progressive